Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 8/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 6/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2723367 | 0.89 | L3MBTL1 (0.54) | MAPTSMN1; SMN2RAB9ANPC1TP53 | |
| SCHEMBL8888157 | 0.80 | NPC1 (0.75) | MAPTSMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL10246587 | 0.76 | PLAU (0.53) | MAPTSMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL23011785 | 0.76 | KMT2A (0.57) | MAPTSMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL31311058 | 0.74 | TMPRSS4 (0.53) | TSHRMAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL31311144 | 0.72 | NPC1 (0.65) | TSHRSMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL2833360 | 0.72 | NPC1 (0.65) | TSHRSMN1; SMN2RAB9AKDM4ENPC1 | |
| SCHEMBL10246590 | 0.72 | ALDH1A1 (0.51) | TSHRMAPTSMN1; SMN2RAB9APOLB | |
| SCHEMBL1579925 | 0.72 | KMT2A (0.68) | TSHRMAPTSMN1; SMN2RAB9AKDM4E | |
| SCHEMBL17354442 | 0.71 | MEN1 (0.71) | MAPTSMN1; SMN2RAB9AKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| WO-2012059442-A2 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | MTPN, CHRNA7, CHRNA10 | TSHR 105/4885MAPT 1060/4885SMN1; SMN2 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.